Pancreatic Cancer: Feasibility and Outcome After Radiochemotherapy with High Dose External Radiotherapy for Non-resected and R1 Resected Patients
| Autor: | Marc Kueng, Pierre-Alain Tercier, Sandrine U Thalmann, Géraldine Risse, Bernhard Egger, Abdelkarim S. Allal, Peter A Kuhn, David Cédric Lauffer |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Single Center survival Gastroenterology 03 medical and health sciences 0302 clinical medicine high dose Pancreatic cancer Internal medicine pancreatic adenocarcinoma medicine 030212 general & internal medicine radiotherapy Chemotherapy business.industry toxicities General Engineering Correction Retrospective cohort study medicine.disease Gemcitabine Radiation therapy Oncology General Surgery 030220 oncology & carcinogenesis Concomitant Radiation Oncology Adenocarcinoma business medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| DOI: | 10.7759/cureus.2713 |
| Popis: | Background Non-resected locally advanced and microscopic positive-margin resected (R1) pancreatic adenocarcinoma are associated with a dismal prognosis. The combination of high dose radiotherapy and concomitant chemotherapy is among the strategies that are used to improve the outcome. The aims of this study were to evaluate the acute and late toxicities and patients' outcome in a retrospective study from a single center. Material and methods From 2009 to 2015, 24 patients, with non-resected locally advanced or R1 resected pancreatic adenocarcinoma, have been treated with concomitant radiochemotherapy, with a median dose of 60 Gy and gemcitabine (50 mg/m2 administered bi-weekly). The acute and late toxicities were evaluated during and after the treatment. Results The actuarial overall survival rates were 39% at 24 months and 8.6% at 36 months. The disease-free survival rates were 32.5% at 24 months and 12.2% at 36 months. Acute toxicities were mainly grade 1 (G1) to grade 2 (G2) except for one patient who presented with severe digestive bleeding potentially linked to the treatment. Late toxicities consisted mainly of G1 digestive toxicities. Conclusion This study confirms the feasibility of high dose radiotherapy combined with gemcitabine-based chemotherapy in patients with locally advanced pancreatic adenocarcinoma. While the outcome remains unsatisfactory, some patients seem to have benefited from this aggressive therapy, which merits to be investigated further. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|